Barclays raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $58 from $57 and keeps an Overweight rating on the shares. The firm says Dawnzera was approved by the FDA on time with a largely comparable label versus Takhzyro and Andembry.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $64 from $63 at BofA
- Ionis Pharmaceuticals’ Dawnzera: A Promising New Entrant in HAE Treatment with Strong Market Potential
- Ionis Pharmaceuticals: Strategic Positioning and Revenue Potential Boost Buy Rating
- Ionis Pharmaceuticals price target raised to $43 from $38 at Stifel
- Ionis Pharmaceuticals Gains FDA Approval for DAWNZERA